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Apolipoprotein E (APOE) has a common polymorphism determined by variation at codon 
112 and 158 resulting in three different haplotypes APOE ε2 (TT), APOE ε3 (TC), and 
APOE ε4 (CC). Due to the strong linkage disequilibrium between the two sites, normally 
three rather than four haplotypes are observed. While genotyping samples from the 
Indianapolis-Ibadan Dementia Project, a longitudinal, community-based study that seeks to 
identify risk factors for dementia in elderly African-Americans living in Indianapolis, 
Indiana, and in elderly Yoruba residing in Ibadan, Nigeria, the fourth APOE haplotype (CT) 
was discovered in a healthy 70 year-old Yoruba subject.
The local Institutional Review Boards have approved the study and informed consent was 
obtained from each participating individual. Genomic DNA was isolated from blood and 
APOE was genotyped as described [Hixson and Vernier 1990]. Amplified products resulting 
in an unusual HhaI pattern were sequenced. Serum was used to measure levels of various 
biomarkers. Lipoproteins were fractionated by gel filtration or agarose electrophoresis [Deeg 
et al., 2001].
A sample from a healthy 70 year-old Yoruba female gave a unique HhaI banding pattern 
(Fig. 1 available in supplementary data). The sequence showed a C at the first nucleotide of 
codon 112 in both alleles and a C and T at the first nucleotide of codon 158 (data not 
shown). One gene would code for apoE4 (Arg112-Arg158) and the other would code for a 
unique apoE protein (Arg112-Cys158). The subject’s 34 year-old son had the same genotype 
and her 67 year-old brother had an ε2/ε4 genotype (Fig. 2 available in supplementary data). 
Since the rare CT haplotype in combination with the frequent APOE ε3 TC haplotype would 
give an APOE ε2/ε4 HhaI digestion pattern and would not be distinguished by direct 
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sequencing, all samples resulting in a ε2/ε4 genotype were digested with restriction enzymes 
AflIII and HaeII (New England Biolabs, Beverly, MA) [Chapman et al., 1996]. The CT 
haplotype was not found in the subject’s brother or the remaining samples from Ibadan and 
Indianapolis. In addition, the subject’s total cholesterol, triglycerides, LDL, HDL, folate 
insulin, glucose and TSH levels were all within normal limits. Fractionation of lipoproteins 
by gel filtration and agarose gel electrophoresis revealed a normal distribution of 
lipoproteins.
The CT haplotype has been reported once before (Genbank accession number AY077451) in 
an Italian autistic child and his normal mother and was named APOE ε3r because the 
cysteine and arginine are in reverse order (Arg112-Cys158) compared to apoE3 (Cys112-
Arg158) [Persico et al., 2004]. We have decided to rename this haplotype APOE ε1Y 
because it would be the next haplotype counting backwards since ε4 is the ancestral 
haplotype. We added the Y for Yoruba to differentiate between the other ε1 proteins already 
described, which are ε2 or ε3 variants that contain mutations at different amino acids and 
run faster using protein electrophoresis [Ando et al., 1999; Gregg et al., 1983; Hoffer et al., 
1996; Moriyama et al., 1992; Steinmetz et al., 1990; Weisgraber et al., 1984].
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